SCHEDULE: FMR LLC Boosts Zenas Biopharma Stake to 7.9%

FMR LLC and Abigail P. Johnson reported a 7.9% beneficial ownership stake in Zenas Biopharma Inc. as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 2 to Schedule 13G for Zenas Biopharma Inc.
• The filing reports beneficial ownership of 3,323,534 shares of Zenas Biopharma Inc. common stock.
• This represents 7.9% of the total outstanding common stock.
• The event date requiring this filing was June 30, 2025.
• FMR LLC holds sole voting power over 3,322,656 shares and sole dispositive power over 3,323,534 shares.
• Abigail P. Johnson holds sole dispositive power over 3,323,534 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• FMR LLC is classified as a parent holding company or control person.
• Abigail P. Johnson is classified as an individual.
• Subsidiaries of FMR LLC, including FIAM LLC (Investment Adviser) and Fidelity Management & Research Company LLC (Investment Adviser), beneficially own shares. Fidelity Institutional Asset Management Trust Company (Bank) is also listed.
• No single other person's interest in the common stock is more than five percent of the total outstanding.

Sentiment

Score: 7

Explanation: The filing indicates a stable, significant institutional holding by a major asset manager, FMR LLC, and its CEO, Abigail P. Johnson, in Zenas Biopharma Inc. This suggests continued confidence from a prominent investor, which is generally a positive signal. The holding is stated to be for ordinary course investment, not for control, implying a long-term, passive interest. While not a performance report, the maintenance of a large stake by a reputable firm is a favorable indicator.

Positives

• A significant institutional investor, FMR LLC, maintains a substantial stake, indicating continued confidence in Zenas Biopharma Inc.
• The holding is for investment purposes in the ordinary course of business, not for control, suggesting a stable long-term investment.

Risks

• No specific operational or financial risks related to Zenas Biopharma Inc. are disclosed in this beneficial ownership filing.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding Zenas Biopharma Inc.'s future operations or financial performance.

Industry Context

The filing indicates continued institutional interest in the biopharma sector, with a major asset manager like FMR LLC maintaining a significant position in Zenas Biopharma Inc. This suggests that Zenas Biopharma Inc. remains on the radar of large investment firms, which is a common trend for companies in the biotechnology and pharmaceutical industries that are often subject to significant institutional investment due to their growth potential and specialized nature.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like FMR LLC may instill confidence and potentially stabilize the stock, signaling a long-term investment perspective.
• Company Management: The presence of a large, passive institutional investor can provide a degree of stability and validation for the company's strategic direction, as the investor is not seeking to influence control.

Key Dates

Recommendation

This Schedule 13G filing indicates that FMR LLC and Abigail P. Johnson maintain a significant 7.9% beneficial ownership stake in Zenas Biopharma Inc. as of June 30, 2025. This is a disclosure of an existing, substantial institutional holding, not a new investment or a change in investment thesis. The filing explicitly states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. For a seasoned investor, this filing primarily confirms continued institutional interest and stability in the ownership structure, rather than signaling a new catalyst for 'buy' or 'sell' action. Therefore, a 'hold' recommendation is appropriate, as the filing does not present new information that would fundamentally alter the investment outlook, but rather reinforces the existing institutional confidence.

Keywords

Zenas Biopharma Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, Equity Stake